Dec 29 2009
Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) is pleased to
announce the execution of an exclusive option agreement with
ThromboVision, Inc. ThromboVision, a Houston-based healthcare
diagnostics company committed to enabling people to lead longer and
healthier lives, has developed and patented T-Guide®, a new cutting-edge
diagnostic test to assist medical professionals with the treatment of
heart disease.
“We are excited about the opportunity to work with Emerging Healthcare
Solutions to bring this important medical technology to cardiac patients
worldwide”
Over 50 million Americans take aspirin and Plavix® to prevent heart
attacks and strokes. Up to 30% of
these patients may not respond to their treatment, leaving up to 15
million patients unprotected. ThromboVision’s T-Guide®
responds to this need by providing a simple, inexpensive diagnostic test
that can show a patient’s level of platelet stickiness, and their
responsiveness to their prescribed treatments.
“We are excited about the opportunity to work with Emerging Healthcare
Solutions to bring this important medical technology to cardiac patients
worldwide,” said Dr. Edward Teitel, President of ThromboVision, Inc.
Thrombovision T-Guide® could save thousands of lives by quickly helping
healthcare professionals personalize their patients’ anti-platelet
treatment to help decrease the chances of a patient suffering a recurred
heart attack or stroke. The ThromboVision T-Guide® test provides near
instantaneous information as to the effectiveness of treatments.
The option agreement gives the companies a mutual due diligence review
period prior to completing an investment and profit sharing agreement.
The emphasis in future health care will be on cost control while
maintaining quality care from physicians.
The largest players in the Dow Jones U.S. Healthcare Sector Index are
Johnson & Johnson, (NYSE: JNJ), Pfizer, Inc. (NYSE: PFE), and Merck &
Co. (NYSE: MRK).
http://www.emerginghealthcaresolutionsinc.com/